Trial Profile

Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 16 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eflornithine (Primary) ; Pembrolizumab (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

09 May 2025 Planned End Date changed from 1 Aug 2026 to 1 Aug 2029.
09 May 2025 Planned primary completion date changed from 1 Aug 2025 to 1 Aug 2029.
24 Sep 2024 According to a Panbela Therapeutics media release, first patient has been enrolled in the phase 1 part of this study. Data from the Phase I trial is expected by mid-2025, with a look to start the Phase II trial in 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com